Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis

• Published in: PloS one Vol. 10; no. 3; p. e0119436
• Main Authors: Larrinaga, Gorka, Perez, Itxaro, Sanz, Begoña, Beitia, Maider, Errarte, Peio, Fernández, Ainhoa, Blanco, Lorena, Etxezarraga, María C., Gil, Javier, López, José I.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.03.2015; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis - genetics; Basque people; Biomarkers, Tumor - biosynthesis; Biomarkers, Tumor - genetics; Cancer; Cell differentiation; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - blood; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; Dipeptidyl Peptidase 4 - biosynthesis; Dipeptidyl Peptidase 4 - blood; Dipeptidyl Peptidase 4 - genetics; Dipeptidyl-peptidase IV; Disease-Free Survival; Early Detection of Cancer; Enzymes; Female; Gene expression; Gene Expression Regulation, Neoplastic; Humans; Immunomodulation; Male; Medical prognosis; Middle Aged; mRNA; Mucosa; Neoplasia; Neoplasms; Patients; Polymerase chain reaction; Prognosis; RNA; RNA, Messenger - biosynthesis; RNA, Messenger - genetics; Serine; Serine peptidase; Studies; Survival; Tissues; Transformation; Transformations (mathematics); Tumors; Spain
• DOI: 10.1371/journal.pone.0119436
• ISSN: 1932-6203

Dipeptidyl-peptidase IV (EC 3.4.14.5) (DPPIV) is a serine peptidase involved in cell differentiation, adhesion, immune modulation and apoptosis, functions that control neoplastic transformation. Previous studies have demonstrated altered expression and activity of tissue and circulating DPPIV in several cancers and proposed its potential usefulness for early diagnosis in colorectal cancer (CRC). The activity and mRNA and protein expression of DPPIV was prospectively analyzed in adenocarcinomas, adenomas, uninvolved colorectal mucosa and plasma from 116 CRC patients by fluorimetric, quantitative RT-PCR and immunohistochemical methods. Results were correlated with the most important classic pathological data related to aggressiveness and with 5-year survival rates. Results showed that: 1) mRNA levels and activity of DPPIV increased in colorectal neoplasms (Kruskal-Wallis test, p<0.01); 2) Both adenomas and CRCs displayed positive cytoplasmic immunostaining with luminal membrane reinforcement; 3) Plasmatic DPPIV activity was lower in CRC patients than in healthy subjects (Mann-U test, p<0.01); 4) Plasmatic DPPIV activity was associated with worse overall and disease-free survivals (log-rank p<0.01, Cox analysis p<0.01). 1) Up-regulation of DPPIV in colorectal tumors suggests a role for this enzyme in the neoplastic transformation of colorectal tissues. This finding opens the possibility for new therapeutic targets in these patients. 2) Plasmatic DPPIV is an independent prognostic factor in survival of CRC patients. The determination of DPPIV activity levels in the plasma may be a safe, minimally invasive and inexpensive way to define the aggressiveness of CRC in daily practice.